Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2020-08-02 Director's Dealing
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - Powell 2 pages 216.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities held by a director, including the number of shares before and after the change, the nature of the interest, and the date of change. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of Director's Dealing filings. The document length is 3553 characters, which is consistent with a detailed director dealing notice rather than a full report or announcement. Therefore, the correct classification is Director's Dealing (DIRS).
2020-08-02 English
Quarterly Business Update & Appendix 4C 9 pages 453.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY BUSINESS UPDATE' and contains detailed financial and operational information for the quarter ended 30 June 2020. It includes cash position, R&D tax refund, updates on research programs, commercial progress, corporate updates including appointments and acquisition details, and financial figures such as cash used in operating activities and investing activities. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content is consistent with a comprehensive quarterly financial and business report, including actual financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2020
2020-07-29 English
Appendix 2A - Issue of Scheme Shares 14 pages 250.3KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities to be quoted, and the circumstances of the issue, specifically related to a scheme of arrangement approved by the Federal Court. This type of document is a regulatory announcement related to capital markets and securities issuance, not a financial report or earnings release. It is not an annual report, interim report, or any form of audit or management report. It is also not a proxy statement, voting result, or remuneration report. The document is a formal regulatory filing to the exchange to list new securities following a corporate action. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-28 English
SDX: Implementation of Scheme of Arrangement 2 pages 132.6KB
Merger & Acquisition Classification · 95% confidence The document is an ASX release announcing the implementation of a Scheme of Arrangement involving the acquisition of Sienna Cancer Diagnostics Limited by BARD1 Life Sciences Limited. It details the share issuance to former Sienna shareholders, changes to the boards of both companies, and the intention to delist Sienna from the ASX. The content focuses on corporate actions related to a merger/acquisition and delisting, with no financial statements or detailed financial performance data. The key elements are the implementation of a scheme (a merger/acquisition event) and the removal from the official list (delisting). Given the prominence of the Scheme of Arrangement and share issuance as consideration, the primary classification is Merger & Acquisition (MA). However, since there is also a clear statement about the intention to delist shares, the document also fits the Delisting Announcement (DLST) category. The document is relatively short (3535 characters) and is an announcement rather than a full report. The main focus is on the merger implementation and share issuance, which aligns best with Merger & Acquisition filings. Therefore, the most appropriate classification is MA with high confidence.
2020-07-27 English
BARD1 COMPLETES SIENNA ACQUISITION 5 pages 210.5KB
M&A Activity Classification · 95% confidence The document is an announcement from BARD1 Life Sciences Limited regarding the completion of the acquisition of Sienna Cancer Diagnostics. It details the acquisition completion, changes in the board of directors and senior management, relocation of the head office, and strategic business plans following the acquisition. The content focuses on corporate actions such as mergers and acquisitions, leadership appointments, and strategic direction rather than financial results or detailed financial statements. There is no indication of financial report data, audit information, or earnings release. The primary focus is on the acquisition and related corporate governance changes. Therefore, the document fits best under the category of M&A Activity (TAR) due to the acquisition announcement and related corporate changes, or Board/Management Information (MANG) due to the board and management changes. However, since the acquisition is the central theme and the document extensively discusses the acquisition completion and its implications, the most appropriate classification is M&A Activity (TAR).
2020-07-27 English
Appointment of Chief Scientific Officer 2 pages 183.8KB
Board/Management Information Classification · 95% confidence The document is a company announcement about the appointment of a new Chief Scientific Officer (CSO) and changes in the leadership team following an acquisition. It focuses on management changes and leadership roles rather than financial results, regulatory filings, or shareholder votes. There is no indication of financial data, report publication, or regulatory compliance content. The content fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2020-07-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.